Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31678106 | 0.86 | TRPV1 (0.52) | TRPV1P2RX7HDAC1HDAC6ADORA2A | |
| SCHEMBL14012294 | 0.86 | TRPV1 (0.52) | TRPV1P2RX7HDAC1HDAC6ADORA2A | |
| SCHEMBL5053483 | 0.86 | TRPV1 (0.52) | TRPV1P2RX7HDAC1HDAC6ADORA2A | |
| SCHEMBL26790233 | 0.82 | MTNR1A (0.51) | TRPV1P2RX7HDAC1HDAC6ADORA2A | |
| SCHEMBL30096647 | 0.78 | HDAC1 (0.49) | TRPV1P2RX7HDAC1HDAC6ADORA2A | |
| SCHEMBL4016626 | 0.78 | TRPV1 (0.51) | TRPV1P2RX7HDAC1HDAC6ADORA2A | |
| SCHEMBL31059308 | 0.78 | HDAC1 (0.54) | TRPV1P2RX7HDAC1HDAC6ADORA2A | |
| SCHEMBL5051444 | 0.78 | HDAC1 (0.54) | TRPV1P2RX7HDAC1HDAC6ADORA2A | |
| SCHEMBL5051439 | 0.78 | HDAC1 (0.54) | TRPV1P2RX7HDAC1HDAC6ADORA2A | |
| SCHEMBL14012211 | 0.78 | HDAC1 (0.54) | TRPV1P2RX7HDAC1HDAC6ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3548495-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018102384-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | CAMK1, CAMKK1, CAMK1D | TRPV1 529/4885P2RX7 1871/4885HDAC1 1571/4885 |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | TRPV1 529/4885P2RX7 1871/4885HDAC1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.